Segundo a bula publicada no site da Lilly do Brasil, o Mounjaro apresentado na forma de soluo injetvel, contendo 2,5 mg, 5 mg, 7,5 mg, 10 mg, 12,5 mg ou 15 mg de tirzepatida (princpio ativo) em 0,5 mL
Your provider must evaluate your individual clinical history and current treatment response
Marracci, G

Body composition plateau and refinement: Fat loss continues but at a slower rate the initial rapid improvement gives way to gradual refinement Lean body mass stabilization at a higher set point Serum protein profile changes consistent with improved metabolic health have been documented in subjects receiving CJC-1295 (PMID: 19386527) Recovery and performance: Training capacity reaches a new baseline recovery that felt enhanced at month 1 now feels normal Injury resilience improves as connective tissue remodeling matures Sleep architecture remains optimized with consistent deep sleep patterns Anti-aging markers: Sustained improvements in skin, hair, and nail quality Improved markers on bloodwork for monitoring guidance, see the CJC-1295 bloodwork biomarkers guide General vitality and recovery capacity that users describe as "feeling younger" Important note on cycling: Community protocols commonly cycle CJC-1295 (8-12 weeks on, 4-8 weeks off), typically for cost and to let IGF-1 normalize

Three Evidence-Based Strategies to Restart Weight Loss Dose escalation is the most direct approach if your prescriber determines it's appropriate